Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2024

ESKAPE Pathogens: Antimicrobial Resistance, Epidemiology, Clinical Impact and Therapeutics

This review examines the current epidemiology, clinical impact, resistance mechanisms, and emerging therapeutic strategies for ESKAPE pathogens, which continue to pose major therapeutic challenges despite new antibiotic introductions.
William R. Miller; César A. Arias· Nature Reviews Microbiology· 2024· DOI 10.1038/s41579-024-01054-w

The core problem

The rise of antibiotic resistance and the dwindling antimicrobial pipeline are recognized as emerging threats to public health. The ESKAPE pathogens—*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.—were initially identified as critical multidrug-resistant bacteria for which effective therapies were urgently needed. Now, entering the third decade of the twenty-first century, and despite the introduction of several new antibiotics and antibiotic adjuvants such as novel β-lactamase inhibitors, these organisms continue to represent major therapeutic challenges. These bacteria share key biological features, including adaptations for survival in modern health-care settings, diverse methods for acquiring resistance determinants, and the dissemination of successful high-risk clones worldwide. With the advent of next-generation sequencing, novel tools to track and combat the spread of these organisms have rapidly evolved, alongside renewed interest in non-traditional antibiotic approaches. This Review explores the current epidemiology and clinical impact of this important group of bacterial pathogens and discusses relevant mechanisms of resistance to recently introduced antibiotics that affect their use in clinical settings. Furthermore, it discusses emerging therapeutic strategies needed for effective patient care in the era of widespread antimicrobial resistance.

Innovation

As a narrative review, Miller and Arias synthesize recent advances in understanding ESKAPE pathogens, focusing on molecular epidemiology, clinical impact, emerging mechanisms of resistance, and novel therapeutic approaches. The authors critically evaluate the literature on the epidemiology and clinical impact of these pathogens, the mechanisms of resistance to recently introduced antibiotics, and emerging therapeutic strategies. The review draws on data from peer-reviewed studies, surveillance systems, and clinical trials to provide a comprehensive overview. No primary data collection or meta-analysis was performed; rather, the authors integrate and interpret existing evidence to highlight key challenges and opportunities in the field.
Introduction
The rise of antibiotic resistance and the dwindling antimicrobial pipeline are recognized as emerging threats to public health. The ESKAPE pathogens—*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.—were initially identified as critical multidrug-resistant bacteria for which effective therapies were urgently needed. Now, entering the third decade of the twenty-first century, and despite the introduction of several new antibiotics and antibiotic adjuvants such as novel β-lactamase inhibitors, these organisms continue to represent major therapeutic challenges. These bacteria share key biological features, including adaptations for survival in modern health-care settings, diverse methods for acquiring resistance determinants, and the dissemination of successful high-risk clones worldwide. With the advent of next-generation sequencing, novel tools to track and combat the spread of these organisms have rapidly evolved, alongside renewed interest in non-traditional antibiotic approaches. This Review explores the current epidemiology and clinical impact of this important group of bacterial pathogens and discusses relevant mechanisms of resistance to recently introduced antibiotics that affect their use in clinical settings. Furthermore, it discusses emerging therapeutic strategies needed for effective patient care in the era of widespread antimicrobial resistance.

Why it matters

The authors discuss the implications of these findings for clinical practice and public health. They emphasize that the continued evolution of resistance mechanisms necessitates a multifaceted approach: robust antimicrobial stewardship, infection control measures, and the development of new therapeutics. The review highlights the importance of molecular surveillance to track high-risk clones and resistance determinants, enabling targeted interventions. The authors also note that while novel antibiotics and β-lactamase inhibitors have been developed, resistance has already emerged, underscoring the need for continuous innovation. Non-traditional approaches, such as phage therapy and immunotherapy, hold promise but require further clinical validation. The review concludes that effective patient care in the era of widespread antimicrobial resistance demands a coordinated global effort to develop and implement novel therapeutic strategies, improve diagnostics, and enhance surveillance. The ESKAPE pathogens exemplify the challenges and opportunities in combating multidrug-resistant organisms, and the lessons learned can inform broader efforts against antimicrobial resistance.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…